Could a Mucus-Busting drug help Hard-to-Treat asthma?
NCT ID NCT03994380
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether inhaling a drug called rhDNAse every day for 4 weeks could help adults with neutrophilic asthma, a type of asthma that often doesn't respond well to standard treatments. The drug works by breaking down DNA in lung mucus, making it thinner and easier to cough up. Researchers measured changes in lung function and asthma symptom control to see if the treatment was beneficial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- rhDNAse (a drug that breaks down DNA in mucus, making it easier to clear from the lungs)
- What this could lead to
- If it works, this could point toward a new way to ease breathing and control symptoms for people with neutrophilic asthma.
- What could go wrong
- This is a very small, early-phase pilot study with only 19 participants, so results may not apply to everyone. The drug may not improve lung function or symptoms as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
19 people
The number who actually took part.
- Started
-
Feb 2020
- Finished
-
Dec 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * i. Able to read and sign an Informed Consent Form (ICF) * ii. At least Age 18 * iii. Diagnosis of Asthma with previous source documentation of PC 20 ≤ 16 mg/dl measured by FEV1 and/or reversibility with albuterol of ≥12% in FEV1 * iv. pre-bronchodilator Forced Vital Capacity (FVC) less than 85% predicted AND Serum total MMP9 ≥ 1800 (cut off determined by previous clinical investigation- Medimmune) OR serum IL-8\> 20 pg/ml OR Sputum extracellular DNA ≥ 3.8 µg/mL OR Sputum Neutrophils \> 40% Exclusion Criteria: * i. Pregnancy * ii. Current smoker, smoking within the past year or pack/year history ≥ 10 * iii. Respiratory infection within past 6 weeks * iv. Antibiotics within the past 4 weeks * v. Active lung disease other than asthma * vi. Cancer within the past 5 years (excluding basal cell skin cancer) * vii. Chronic infection due to HIV, HBV, or HCV * viii. Hematologic or autoimmune disease * ix. Unable to safely undergo bronchoscopy as determined by primary or study doctor.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neutrophilic asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Jewish Health
Denver, Colorado, 80206, United States